Palisade Bio (PALI) Stock Forecast, Price Target & Predictions
PALI Stock Forecast
Palisade Bio stock forecast is as follows: an average price target of $1.50 (represents a -60.42% downside from PALI’s last price of $3.79) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
PALI Price Target
The average price target for Palisade Bio (PALI) is $1.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential -60.42% downside from PALI's last price of $3.79.
PALI Analyst Ratings
According to 1 Wall Street analysts, Palisade Bio's rating consensus is 'Buy'. The analyst rating breakdown for PALI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Palisade Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 17, 2023 | Naz Rahman | Maxim Group | $1.50 | $9.07 | -83.46% | -60.42% |
The latest Palisade Bio stock forecast, released on Nov 17, 2023 by Naz Rahman from Maxim Group, set a price target of $1.50, which represents a -83.46% decrease from the stock price at the time of the forecast ($9.07), and a -60.42% decrease from PALI last price ($3.79).
Palisade Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $1.50 |
| Last Closing Price | $3.79 | $3.79 | $3.79 |
| Upside/Downside | -100.00% | -100.00% | -60.42% |
In the current month, the average price target of Palisade Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Palisade Bio's last price of $3.79. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Mar 30, 2023 | Maxim Group | - | Buy | Upgrade |
Palisade Bio's last stock rating was published by Maxim Group on Mar 30, 2023. The company Upgrade its PALI rating from "null" to "Buy".
Palisade Bio Financial Forecast
Palisade Bio Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Jun 12 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $2.50K | $2.50K | $2.92K | $4.17K | $102.50K | $78.13K |
| Avg Forecast | - | - | - | $3.02K | $1.95K | $2.92K | $3.57K | $112.50K | $133.33K |
| High Forecast | - | - | - | $3.63K | $2.34K | $3.50K | $4.29K | $135.00K | $160.00K |
| Low Forecast | - | - | - | $2.42K | $1.56K | $2.33K | $2.86K | $90.00K | $106.67K |
| # Analysts | - | - | - | 19 | 11 | 14 | 11 | 15 | 14 |
| Surprise % | - | - | - | 0.83% | 1.28% | 1.00% | 1.17% | 0.91% | 0.59% |
Palisade Bio's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. PALI's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $2.50K (Mar 17).
Palisade Bio EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Jun 12 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 19 | 11 | 14 | 11 | 15 | 14 |
| EBITDA | - | - | - | $-7.32M | $-6.13M | $-4.52M | $-5.40M | $-3.49M | $-2.33M |
| Avg Forecast | - | - | - | $-8.58M | $-4.41M | $-4.52M | $-4.50M | $-3.88M | $-3.27M |
| High Forecast | - | - | - | $-6.87M | $-3.52M | $-3.61M | $-3.60M | $-3.10M | $-2.61M |
| Low Forecast | - | - | - | $-10.30M | $-5.29M | $-5.42M | $-5.40M | $-4.66M | $-3.92M |
| Surprise % | - | - | - | 0.85% | 1.39% | 1.00% | 1.20% | 0.90% | 0.71% |
undefined analysts predict PALI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Palisade Bio's previous annual EBITDA (undefined) of $NaN.
Palisade Bio Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Jun 12 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 19 | 11 | 14 | 11 | 15 | 14 |
| Net Income | - | - | - | $-7.57M | $-6.61M | $-5.05M | $-5.92M | $-3.59M | $-2.38M |
| Avg Forecast | $-2.86M | $-4.12M | $-3.60M | $-8.88M | $-4.74M | $-5.05M | $-4.93M | $-3.99M | $-3.33M |
| High Forecast | $-2.86M | $-3.77M | $-3.60M | $-7.10M | $-3.80M | $-4.04M | $-3.95M | $-3.19M | $-2.66M |
| Low Forecast | $-2.86M | $-4.46M | $-3.60M | $-10.65M | $-5.69M | $-6.06M | $-5.92M | $-4.79M | $-3.99M |
| Surprise % | - | - | - | 0.85% | 1.39% | 1.00% | 1.20% | 0.90% | 0.71% |
Palisade Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PALI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Palisade Bio SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Jun 12 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 19 | 11 | 14 | 11 | 15 | 14 |
| SG&A | - | - | - | $1.33M | $3.17M | $1.43M | $3.61M | $1.25M | $862.68K |
| Avg Forecast | - | - | - | $467.82K | $301.77K | $451.41K | $552.62K | $17.41M | $20.63M |
| High Forecast | - | - | - | $561.13K | $361.97K | $541.63K | $663.12K | $20.89M | $24.76M |
| Low Forecast | - | - | - | $374.04K | $241.26K | $361.04K | $441.97K | $13.93M | $16.51M |
| Surprise % | - | - | - | 2.85% | 10.51% | 3.17% | 6.53% | 0.07% | 0.04% |
Palisade Bio's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PALI last annual SG&A of $1.33M (Mar 17).
Palisade Bio EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Jun 12 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 19 | 11 | 14 | 11 | 15 | 14 |
| EPS | - | - | - | $-679.23 | $-933.33 | $-732.71 | $-897.35 | $-679.34 | $-571.18 |
| Avg Forecast | $-2.33 | $-3.35 | $-2.93 | $-12.20 | $-0.51 | $-0.78 | $-13.00 | $-13.00 | $-18.20 |
| High Forecast | $-2.33 | $-3.07 | $-2.93 | $-9.76 | $-0.41 | $-0.62 | $-10.40 | $-10.40 | $-14.56 |
| Low Forecast | $-2.33 | $-3.63 | $-2.93 | $-14.64 | $-0.61 | $-0.94 | $-15.60 | $-15.60 | $-21.84 |
| Surprise % | - | - | - | 55.67% | 1830.06% | 939.37% | 69.03% | 52.26% | 31.38% |
According to undefined Wall Street analysts, Palisade Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PALI previous annual EPS of $NaN (undefined).
PALI Forecast FAQ
Is Palisade Bio a good buy?
Yes, according to 1 Wall Street analysts, Palisade Bio (PALI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of PALI's total ratings.
What is PALI's price target?
Palisade Bio (PALI) average price target is $1.5 with a range of $1.5 to $1.5, implying a -60.42% from its last price of $3.79. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Palisade Bio stock go up soon?
According to Wall Street analysts' prediction for PALI stock, the company can go down by -60.42% (from the last price of $3.79 to the average price target of $1.5), down by -60.42% based on the highest stock price target, and down by -60.42% based on the lowest stock price target.
Can Palisade Bio stock reach $6?
PALI's average twelve months analyst stock price target of $1.5 does not support the claim that Palisade Bio can reach $6 in the near future.
What are Palisade Bio's analysts' financial forecasts?
PALI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-10.58M (high $-10.235M, low $-10.924M), average SG&A $0 (high $0, low $0), and average EPS is $-8.613 (high $-8.332, low $-8.893).
Did the PALI's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2017), Palisade Bio's revenue was $2.5K, missing the average analysts' forecast of $3.02K by -17.30%. The company's EBITDA was $-7.316M, missing the average prediction of $-8.583M by -14.75%. Palisade Bio's net income was $-7.567M, missing the average estimation of $-8.877M by -14.75%. The company's SG&A was $1.33M, beating the average forecast of $467.82K by 184.82%. Lastly, the company's EPS was $-679, beating the average prediction of $-12.2 by 5467.48%